Development & Manufacturing Considerations of High Potent Drug Proucts - a CDMO's Perspective | CPhI North America

 

View, browse and sort the ever-growing list of sessions by pass type, track, and format. With this Session Scheduler, you can build your schedule in advance and access it during the show via export or with the Mobile App, once live. Sessions do fill up and seating is first come, first serve, so arrive early to sessions that you would like to attend.

Development & Manufacturing Considerations of High Potent Drug Proucts - a CDMO's Perspective

Anil Kane (Ph.D, MBA, Executive Director, Global Head of Technical & Scientific Affairs, Patheon Inc. part of Thermo Fisher Scientific)

Location: E353b

Date: Tuesday, April 30

Time: 10:30am - 11:15am

Track: Drug Development

Vault Recording: TBD

  • Trends of High Potent API’s and a CDMO view on the future of supporting high potent drug product manufacturing
  • Regulatory considerations in handling special category of compounds in a segregated infrastructure.
  • Case studies and containment solutions in handling potent API’s in drug product manufacturing
  • CDMO view on strategizing supporting high potent API and DP manufacturing support to the pharmaceutical industry